|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 高频超声联合多普勒超声诊断良性胆囊息肉样病变的临床应用价值研究显示文摘目的探讨高频超声联合多普勒超声用于良性胆囊息肉样病变的诊断价值。方法选取于2013年10月至2014年10月收治的110例良性胆囊息肉病变患者作为研究对象,分别采用高频超声联合腹部彩色多普勒超声检查和手术病理学进行检查。对比病理结果观察高频超声联合腹部彩色多普勒超声诊断的准确率。结果术前对所有患者采用高频超声联合腹部多普勒超声诊断为良性胆囊息肉的患者共计110例,经手术病理学检查,胆固醇息肉有56例(50.9%),炎性息肉有25例(22.7%),胆囊结石有13例(11.8%),腺瘤有4例(3.6%),腺癌有3例(2.7%),囊壁腺体结构紊乱有3例(2.7%),腺肌症有3例(2.7%),黏膜下层软结节有3例(2.7%)。对比分析两种检查方法,高频超声联合腹部多普勒超声诊断良性胆囊肉样病变的准确率为96.4%(106/110),与传统的手术病理学检查方法经统计分析,差异无显著性(P>0.05);误诊率为3.6%(4/110)。结论高频超声联合腹部多普勒超声用于良性胆囊息肉的临床诊断,具有诊断准确率较高,可信度较强等优点,可作为胆囊癌前病变的预防依据。 | 严稳开 | 2016 | 临床和实验医学杂志2016，15，12： | 48 |
| 2 | 肝切除联合纤维胆道镜治疗肝胆管结石的疗效分析显示文摘肝胆管结石是临床上胆管结石中较为复杂的一种,常累及肝内外胆管,药物治疗一般难以将结石排出,病情迁延反复难以治愈[1]。结石引起局部感染可导致胆管阻塞,诱发多种严重并发症,对患者造成极大的身心伤害[2]。收集我院54例肝胆管结石患者手术治疗的临床资料,分析肝切除联合纤维胆道镜术与胆总管切开联合纤维胆道镜术的疗效比较, | 肖晶晶 刘兴贵 陈令起 | 2016 | 贵州医药2016，40，5： | 10 |
| 3 | 超声内镜在胆系疾病诊治中的应用进展显示文摘胆道系统毗邻结构复杂,故传统影像学检查难以清晰显示胆道系统。而超声内镜利用置于内镜前端的微型高频超声探头,在消化道管腔内对消化道管壁及邻近脏器进行超声扫查,可以克服气体、脂肪及骨骼的干扰,从而获得清晰的超声图像。因此,它在胆系疾病,尤其是胆总管微小结石、胆总管狭窄及胆囊早期占位性病变等疾病的诊治中具有不可比拟的优势。目前,超声内镜已被广泛应用于胆系疾病的诊断与治疗中,现就其在胆系疾病诊治中的应用进展阐述如下。 | 姜宏雪 郭杰芳 金震东 | 2016 | 中华消化内镜杂志2016，33，8： | 4 |
| 4 | 超声内镜引导下细针穿刺术对消化道周围占位的诊断显示文摘超声内镜引导下细针穿刺术(EUS-FNA)是超声内镜(EUS)引导下介入诊疗的基础。EUS-FNA在消化道管壁外占位性病变的诊断有重要价值。我们对哪些消化道管壁外病变可以行EUS-FNA及其价值以及如何在这些部位行EUS-FNA作简要介绍。 | 丁祥武 | 2017 | 临床内科杂志2017，34，2： | 2 |
| 5 | 胆囊癌的综合诊疗进展显示文摘胆囊癌是一种恶性程度极高的消化系统肿瘤,在我国发病率逐年上升。因其早期缺乏特异性症状,故诊断困难,一经发现往往已是进展期,外科手术仍是可能治愈胆囊癌的唯一手段,故早期诊断对于根治性切除,提高患者总体预后就显得尤为重要,但目前仍缺乏特异性的胆囊癌分子诊断靶标。外科手术技术的不断研究与改良使得胆囊癌的手术方式日趋规范化。随着对胆囊癌流行病学、发病机制认识的逐渐提高及影像学、放化疗等技术的不断进步,近年来胆囊癌的综合诊疗手段也得到了快速发展,但亟需高质量的临床研究作为有力证据。未来,包括根治性手术、辅助放化疗、靶向治疗、免疫治疗等在内的综合治疗模式将是胆囊癌治疗的发展趋势。本文将国内外相关文献介绍胆囊癌综合诊疗发展概况进行了综述。 | 张亦弛 顾劲扬 | 2019 | 国际外科学杂志2019，46，6： | 2 |
| 6 | 多普勒超声与磁共振胰胆管造影对胆道结石诊断价值比较显示文摘目的:分析磁共振胰胆管成像(MRCP)检查诊断胆道结石患者的临床价值。方法:我院836例腹腔镜下胆囊切除术患者入院前均接受多普勒超声和MRCP检查,手术胆道探查、逆行胰胆管造影取出结石则为诊断胆道结石的金标准,分析两种检查方法的诊断价值。结果:MRCP诊断胆总管结石的特异度、敏感度、准确度、阳性预测值、阴性预测值均显著高于彩超诊断(P〈0.05)。结论:MRCP诊断胆总管结石高度可疑患者明显优于多普勒超声,术前常规行MRCP检查具有重要的临床意义。 | 史玉爽 杨媚 | 2015 | 按摩与康复医学2015，6，8： | 1 |
| 7 | The efficacy and safety of endoscopic ultrasound-guided fine-needle biopsy in gallbladder masses显示文摘Background: Endoscopic ultrasound-guided fine-needle biopsy(EUS-FNB) is a widely used modality for acquiring various target samples, but its efficacy in gallbladder masses is unknown. The aim of this retrospective study was to evaluate the efficacy and safety of EUS-FNB in patients with gallbladder masses. Methods: The study samples were composed of patients from March 2015 to July 2019 who needed to identify the nature of gallbladder masses through EUS-FNB. The outcomes of this study were the adequacy of specimens, diagnostic yields, technical feasibility, and adverse events of the EUS-FNB in gallbladder masses. Results: A total of 27 consecutive patients with a median age of 58 years were included in this study. The 22-gauge FNB needle was feasible in all lesions. The median follow-up period of the patients was 294 days. The specimens sufficient for diagnosis account for 89%(24/27) and 93%(25/27) in cytology and histology, respectively. The overall diagnostic yields for malignancy showed the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 95.45% [95% confidence interval(CI): 75.12%-99.76%], 100%(95% CI: 46.29%-10 0%), 10 0%(95% CI: 80.76%-100%), 83.33%(95% CI: 36.48%-99.12%), and 96.30%(95% CI: 80.20%-99.99%), respectively. The subgroup analysis revealed that FNB could obtain sufficient specimens and high diagnostic yields in both gallbladder mass < 20.5 mm group and ≥20.5 mm group. One patient experienced mild abdominal pain after the procedure and recovered within one day. Conclusions: EUS-FNB is a reasonable diagnostic tool for the pretreatment diagnosis of patients with gallbladder masses, especially for patients who may miss the opportunity of surgery and need sufficient specimens to identify the pathological type so as to determine chemotherapy regimens. Further largescale studies are needed to confirm our conclusion. | Ting Tong Li Tian Min-Zi Deng Xue-Jie Chen Tian Fu Ke-Jia Ma Jia-Hao Xu Xiao-Yan Wang | 2023 | Hepatobiliary & Pancreatic Diseases International2023，22，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员